BCL2L1 and pancreatic neoplasm: Greater Bcl-xL expression has been associated with resistance to TRAIL-induced apoptosis in breast and pancreatic cancer cells [37, 38], and inhibition or knockdown of Bcl-xL has been demonstrated to sensitize select TRAIL-resistant pancreatic cancer cell lines to TRAIL-mediated apoptosis [38, 39].